Women’s bodies are not hormonally static. Across a menstrual cycle, estrogen and progesterone rise and fall in predictable patterns, influencing mood, sleep, energy, cognition, stress sensitivity, and the way we experience our bodies.
So it raises an interesting question:
Could the timing of ketamine therapy within a woman’s menstrual cycle influence how she responds to it?
The honest answer is: possibly, but we don't know enough yet to say exactly when ketamine works best.
The research is still emerging, but there is enough biological evidence to make the question worth asking.
Ketamine's rapid antidepressant effects are thought to involve the brain's glutamate system and a cascade of changes associated with synaptic plasticity (the brain's ability to form and strengthen neural connections).
And this is where ovarian hormones become particularly interesting.
Estrogen doesn't simply regulate reproduction. It acts throughout the brain and can influence neurotransmitters, neural connectivity, inflammation, and neuroplasticity. Because ketamine also appears to work partly through mechanisms involving neuroplasticity, researchers have begun investigating whether estrogen and progesterone can influence ketamine's effects.
A 2022 review examining sex differences in ketamine treatment concluded that sex hormones, particularly estrogen and progesterone, can influence ketamine's effects at multiple biological levels. The authors suggested that the menstrual-cycle phase may eventually be worth considering when treating women with ketamine, but also emphasized the significant gaps in human research.
Some of the most interesting evidence comes from studies in female mice.
In one study, researchers found that female mice were more sensitive to the antidepressant-like effects of low-dose ketamine during proestrus, the phase of the mouse reproductive cycle associated with higher estrogen. A dose that did not produce the same effect during another phase of the cycle did produce an antidepressant-like response when estrogen was higher. The researchers linked this effect to estrogen receptors and changes in proteins involved in synaptic plasticity.
Other rodent research has similarly found that estrogen and progesterone can influence sensitivity to ketamine.
This is fascinating for sure, but it is also where we need to slow down.
Mice are not women.
Animal studies can help us understand biological mechanisms and generate hypotheses, but they cannot tell us that a woman should schedule her ketamine session around ovulation.
And not every animal study has found that the cycle phase changes ketamine's effects.
This is where the evidence becomes much thinner.
A randomized clinical trial of ketamine for treatment-resistant depression included both men and women and examined whether reproductive status and hormone levels influenced treatment response. The researchers did not find significant differences in ketamine response based on sex or menopausal status, and baseline estradiol and progesterone levels were not significantly associated with treatment response.
However, there was an important limitation:
The study was not designed to determine whether the menstrual-cycle phase at the time of ketamine administration mattered. In other words, it doesn't answer the question we're asking.
A systematic review of clinical studies similarly found that the vast majority of existing research has not demonstrated meaningful sex differences in ketamine's antidepressant response, and very few studies have specifically investigated the role of reproductive hormones or cycle phase.
So today, we have an intriguing biological hypothesis without enough human data to turn it into a clinical rule.
Potentially.
The menstrual cycle is often described in four phases: menstrual, follicular, ovulatory, and luteal. Estrogen and progesterone fluctuate substantially across these phases, and many women notice corresponding changes in mood, energy, sensitivity, and emotional processing.
It is therefore reasonable to wonder whether those hormonal shifts could influence the subjective experience of ketamine.
Interestingly, a small human study examining ketamine for postoperative pain found that women in the luteal phase showed a trend toward lower pain scores after surgery. But the study included only 22 women and was investigating pain relief and not ketamine-assisted psychotherapy or depression treatment.
This is an important distinction.
We don't yet know whether the menstrual phase changes the therapeutic effects of ketamine, the subjective experience, side effects, or some combination of these.
Not necessarily. There is currently not enough evidence to recommend that every woman receive ketamine during a particular phase of her cycle.
In fact, the research raises competing possibilities.
Some preclinical evidence suggests that higher estrogen may enhance ketamine's effects on neuroplasticity. Other researchers have proposed that administering ketamine near the beginning of the follicular phase (when estrogen and progesterone are relatively low) could potentially reduce certain risks or side effects.
These ideas are not yet established clinical recommendations.
And there is another important consideration: your individual experience may matter more than a theoretical "optimal" cycle day.
One of the advantages of a longitudinal, physician-guided approach to ketamine therapy is that we don't have to assume every woman's brain will respond in exactly the same way.
If you menstruate, your cycle can become another piece of information we pay attention to, but not something that dictates your treatment.
For example, over several sessions, you might begin to notice:
Those observations can be valuable.
Rather than forcing women into a one-size-fits-all protocol, we can begin to develop a more nuanced understanding of your nervous system, your hormonal rhythm, and your response to treatment.
The emerging research around ketamine and the menstrual cycle points toward something larger: Women's biology deserves to be part of the conversation when we study and practice psychedelic medicine.
For decades, much of medical research has treated the male body as the default and the female body as a variation. We are increasingly recognizing that sex hormones can influence the brain, nervous system, immune system, metabolism, and response to medications.
Ketamine may be another place where this matters.
We aren't at the point where science can tell a woman, "Take ketamine on day 12 of your cycle for the best results."
But we may be at the point where it's worth asking a better question:
What happens when we stop treating the female body as background information and instead start listening to its rhythms as part of the healing process?
At Medicine Within, that's the kind of question we're interested in exploring: where neuroscience, medicine, embodiment, and the lived experience of being human meet. Clinically, we have noticed that women respond differently during different parts of their cycle. How to use this information to optimize treatment and reduce side effects remains an open question.
We don't yet have clinical trials that tell us the optimal day of a woman's menstrual cycle to receive ketamine as the research on menstrual-cycle timing and ketamine remains limited. What we have instead is a combination of intriguing animal research, a small human pain study, and human psychiatric studies that have examined sex, reproductive status, or hormone levels without adequately testing menstrual-cycle timing itself.
Cycle tracking should not be used to change medication timing or dosing without guidance from your prescribing clinician.
Research & References
“Behavioral and biochemical sensitivity to low doses of ketamine: Influence of estrous cycle in C57BL/6 mice”
DOI: 10.1016/j.neuropharm.2017.11.022
“Sex differences in response to ketamine as a rapidly acting intervention for treatment resistant depression”
DOI: 10.1016/j.jpsychires.2019.01.010
“Sex Differences in the Behavioral, Molecular, and Structural Effects of Ketamine Treatment in Depression”
DOI: 10.1093/ijnp/pyab082
“Menstrual cycle-related variations in postoperative analgesia with the preemptive use of N-methyl-D-aspartate antagonist ketamine: a pilot study”
PubMed — Lenzmeier et al. 2008
DOI: 10.1097/01.DCC.0000338875.08153.6f
“Sex differences in the antidepressant-like effects of ketamine”
PubMed — Carrier & Kabbaj 2013
“Aromatase inhibition and ketamine in rats: sex-differences in antidepressant-like efficacy”
PubMed — Ledesma-Corvi et al. 2023
DOI: 10.1186/s13293-023-00560-5
“Sex differences in ketamine's therapeutic effects for mood disorders: A systematic review”
DOI: 10.1016/j.psychres.2022.114579
“Sex differences in ketamine treatment for depressive disorders: A systematic review”
ScienceDirect — Feng et al. 2025
DOI: 10.1016/j.pnpbp.2025.111521
.jpg)
Receive news, articles, and blog posts highlighting the benefits of ketamine therapy!
